Compare Amgen, Inc. (AMGN) vs Zscaler Inc (ZS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Zscaler Inc — how do they compare? Amgen, Inc. trades at $367.08 (market cap $196.12B), while Zscaler Inc trades at $139.31 (market cap $22.52B). The key difference: Amgen, Inc. is far larger — about 8.7× Zscaler Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| AMGN | ZS | |
|---|---|---|
Market Cap | $196.12B | $22.52B |
Sector | Health | Technology |
52-Week High | $388.16 | $336.27 |
52-Week Low | $271.18 | $118.05 |
Enterprise Value | $241.41B | $20.84B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Zscaler (ZS) trades at $139.27, down 5.34% on the day, amid mixed signals. The stock shows strong revenue growth with 2025 revenue reaching $2.67 billion and consistent quarterly EPS beats, but remains unprofitable with a net income margin of -2.44%. Technical indicators are bullish on moving averages but show overbought RSI levels. Recent news highlights class action investigations and AI infrastructure cost pressures, yet analyst sentiment remains overwhelmingly positive with a consensus price target of $192.64.
The outlook for ZS is cautiously optimistic driven by robust cybersecurity demand and AI security traction, but risks include profitability challenges, rising costs, and legal scrutiny. Wall Street maintains a strong buy consensus (79% buy ratings), suggesting significant upside potential if execution improves and margins stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
